Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

Ronan Joseph Kelly, Olivier Rixe

Research output: Contribution to journalArticle

Abstract

An improved understanding of the molecular biology involved in many solid tumors has led to the development of novel targeted agents. Axitinib is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1, 2, and 3. This review presents preclinical and clinical data available for axitinib, including findings from key phase II clinical trials in a wide variety of tumors including melanomas and renal, pancreatic, thyroid, breast, lung, and colorectal carcinomas. The differences between axitinib and other VEGFR inhibitors are explored and details of the possible use of blood pressure elevation and erythropoietin blood levels as predictive markers of VEGF/VEGFR pathway inhibition are outlined. Ongoing Phase III studies in pancreatic and metastatic renal cell carcinoma should help to determine the optimum utilization of these agents at the appropriate stage of disease.

Original languageEnglish (US)
Pages (from-to)297-305
Number of pages9
JournalTargeted Oncology
Volume4
Issue number4
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor
TYK2 Kinase
Phase II Clinical Trials
Erythropoietin
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Molecular Biology
Colorectal Neoplasms
Melanoma
Neoplasms
Thyroid Gland
Breast Neoplasms
Blood Pressure
Kidney
Lung
axitinib

Keywords

  • Axitinib
  • Pancreatic carcinoma
  • Renal cell carcinoma
  • Tyrosine kinese inhibitor
  • VEGF receptor inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. / Kelly, Ronan Joseph; Rixe, Olivier.

In: Targeted Oncology, Vol. 4, No. 4, 12.2009, p. 297-305.

Research output: Contribution to journalArticle

Kelly, Ronan Joseph ; Rixe, Olivier. / Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. In: Targeted Oncology. 2009 ; Vol. 4, No. 4. pp. 297-305.
@article{2c9ec9195a0543709acfb4284f9ec14d,
title = "Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor",
abstract = "An improved understanding of the molecular biology involved in many solid tumors has led to the development of novel targeted agents. Axitinib is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1, 2, and 3. This review presents preclinical and clinical data available for axitinib, including findings from key phase II clinical trials in a wide variety of tumors including melanomas and renal, pancreatic, thyroid, breast, lung, and colorectal carcinomas. The differences between axitinib and other VEGFR inhibitors are explored and details of the possible use of blood pressure elevation and erythropoietin blood levels as predictive markers of VEGF/VEGFR pathway inhibition are outlined. Ongoing Phase III studies in pancreatic and metastatic renal cell carcinoma should help to determine the optimum utilization of these agents at the appropriate stage of disease.",
keywords = "Axitinib, Pancreatic carcinoma, Renal cell carcinoma, Tyrosine kinese inhibitor, VEGF receptor inhibitor",
author = "Kelly, {Ronan Joseph} and Olivier Rixe",
year = "2009",
month = "12",
doi = "10.1007/s11523-009-0126-9",
language = "English (US)",
volume = "4",
pages = "297--305",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

AU - Kelly, Ronan Joseph

AU - Rixe, Olivier

PY - 2009/12

Y1 - 2009/12

N2 - An improved understanding of the molecular biology involved in many solid tumors has led to the development of novel targeted agents. Axitinib is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1, 2, and 3. This review presents preclinical and clinical data available for axitinib, including findings from key phase II clinical trials in a wide variety of tumors including melanomas and renal, pancreatic, thyroid, breast, lung, and colorectal carcinomas. The differences between axitinib and other VEGFR inhibitors are explored and details of the possible use of blood pressure elevation and erythropoietin blood levels as predictive markers of VEGF/VEGFR pathway inhibition are outlined. Ongoing Phase III studies in pancreatic and metastatic renal cell carcinoma should help to determine the optimum utilization of these agents at the appropriate stage of disease.

AB - An improved understanding of the molecular biology involved in many solid tumors has led to the development of novel targeted agents. Axitinib is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1, 2, and 3. This review presents preclinical and clinical data available for axitinib, including findings from key phase II clinical trials in a wide variety of tumors including melanomas and renal, pancreatic, thyroid, breast, lung, and colorectal carcinomas. The differences between axitinib and other VEGFR inhibitors are explored and details of the possible use of blood pressure elevation and erythropoietin blood levels as predictive markers of VEGF/VEGFR pathway inhibition are outlined. Ongoing Phase III studies in pancreatic and metastatic renal cell carcinoma should help to determine the optimum utilization of these agents at the appropriate stage of disease.

KW - Axitinib

KW - Pancreatic carcinoma

KW - Renal cell carcinoma

KW - Tyrosine kinese inhibitor

KW - VEGF receptor inhibitor

UR - http://www.scopus.com/inward/record.url?scp=72449131348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449131348&partnerID=8YFLogxK

U2 - 10.1007/s11523-009-0126-9

DO - 10.1007/s11523-009-0126-9

M3 - Article

C2 - 19876699

AN - SCOPUS:72449131348

VL - 4

SP - 297

EP - 305

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 4

ER -